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ABSTRACT
Background The Spectrum projection package uses
estimates of national HIV incidence, demographic data
and other assumptions to describe the consequences of
the HIV epidemic in low and middle-income countries.
The default parameters used in Spectrum are updated
every 2 years as new evidence becomes available to
inform the model. This paper reviews the default
parameters that deﬁne the course of HIV progression
among adults and children in Spectrum.
Methods For adults, data available from published and
grey literature and data from the ART-LINC International
epidemiologic Database to Evaluate AIDS (IeDEA)
collaboration were combined to estimate survival among
those who started antiretroviral therapy (ART). For
children, a review of published material on survival on
ART and survival on ART and cotrimoxazole was used to
derive survival probabilities. Historical data on the
distribution of CD4 cell counts and CD4 cell percentages
by age among children who were not treated (before
treatment was available) were used to progress children
from seroconversion to different CD4 cell levels.
Results Based on the updated evidence estimated
survival among adults aged over 15 years in the ﬁrst year
on ART was 86%, while in subsequent years survival
was estimated at 90%. Survival among children during
the ﬁrst year on ART was estimated to be 85% and for
subsequent years 93%.
Discussion The revised default parameters based on
additional data will make Spectrum estimates more
accurate than previous rounds of estimates.
Every 2 years UNAIDS and partners support low
and middle-income countries to create national
estimates and projections of their HIV epidemics
with modelling software. The estimation and
projection package (EPP) is used to create a national
HIV incidence curve.
1 The Spectrum computer
package then uses the HIV incidence curve to
project the impact.
2
To make accurate estimates and projections
countries must populate EPP and Spectrum with
HIV sentinel surveillance data, HIV prevalence
from population-based surveys (if available) and
programme data such as the number of women
receiving antiretroviral prophylaxis to prevent
mother-to-child transmission of HIV and the
number of adults receiving antiretroviral therapy
(ART). In addition, EPP and Spectrum use
numerous parameters that determine how HIV
progresses in a given individual and how it affects
the demographic structure of the population. Of
speciﬁc importance for estimating ART needs and
its impact are parameters that describe the time
from HIV seroconversion until the need for treat-
ment and the time from treatment until death. If
countries have local studies that capture these
parameters, the country-speciﬁc data can be used in
the model, reﬂecting the situation in their country.
If no data are available from the country on the
speciﬁc parameter default parameters are used in
the model.
Outputs of Spectrum include the number of
people living with HIV, estimated HIV prevalence,
number of deaths due to AIDS, number of people in
need of ART, number of HIV-positive pregnant
women in need of antiretroviral prophylaxis to
avoid transmission to children, and the estimated
number of orphans due to AIDS. The Spectrum
outputs are used by countries to develop their
national strategic plans, to identify and set treat-
ment targets, and to estimate the impact of ART
and prevention of mother-to-child transmission
programmes at the population level.
3e5 The models
thus need to be as accurate as possible and should
precisely reﬂect the current level of the epidemic in
the speciﬁc country.
As more data become available from ART
programmes and cohort studies, the default
parameters used in Spectrum are updated and
improved. Here we describe how the default
parameters related to HIV progression were deter-
mined for the version of Spectrum used in the 2009
round of national HIV estimates. In particular, we
explain the derivation of parameters on: serocon-
version to eligibility for treatment for adults and
children; survival among those starting on ART in
the ﬁrst year on ART and in subsequent years, for
adults and children.
Spectrum is a compartmental model covering
three epidemic states (HIV negative, HIV positive
and not in need of treatment, and HIV positive and
in need of treatment) and death. It is a discrete
model based on age groups. The population data
used in Spectrum come from the UN Population
Division’s population prospects 2008 revision.
More information on Spectrum is available else-
where.
2 6
ADULTS
In Spectrum survival time from seroconversion to
death is split into two periods: time from sero-
conversion to eligibility for treatment and time
from eligibility for treatment until death. The
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Supplementpatterns describing overall progression from new seroconversion
to AIDS death without treatment have not changed since the
2008 round of estimates and are described elsewhere.
7 8 In brief,
the progression patterns are based on demographic surveillance
sites in the ALPHA network in the absence of ART.
9
Progression from seroconversion to eligibility for treatment
As early as 2005 low and middle-income countries started
changing national guidelines to initiate individuals on ART
earlier in the course of HIV disease progression. To reﬂect these
changes, Spectrum now includes an option allowing countries to
change adult eligibility criteria for ART in the model. The
version of Spectrum used in 2009 assumes that eligibility was
deﬁned initially as all HIV-infected adults with a CD4 cell count
under 200 cells/mm
3. If eligibility criteria have changed they can
be deﬁned as CD4 cell counts under 250 or 350 cells/mm
3 and
the year the change was implemented. The time from serocon-
version until the need for treatment is adjusted based on the
eligibility criterion.
The previous version of Spectrum in 2007 used data from the
eligibility for ART in lower income countries collaboration
(eART-linc) to determine time from seroconversion to eligibility
for treatment (assuming eligibility was 200 cells/mm
3). The
eART-linc collaboration compiled data from ﬁve treatment
programmes in low and middle-income countries to measure the
evolution of CD4 cell counts over the progression of the disease.
The ﬁve sites included in the eART-linc data include two sites in
Uganda, two sites in Thailand and one site in Côte d’Ivoire.
10
In the 2009 version of Spectrum the eART-linc results were
again used to describe the time from seroconversion to eligibility
and from eligibility to death using three different eligibility
criteria: CD4 less than 200 cells/mm
3, CD4 less than 250 cells/
mm
3 and CD4 less than 350 cells/mm
3. The progression
patterns were developed by ﬁtting Weibull curves to match the
median progression time to eligibility and to death and
matching the overall pattern of progression from seroconversion
to death as estimated by the ALPHA network cohort studies.
8
The Weibull patterns are implemented in Spectrum by
converting them to annual survival rates as a function of time
since infection.
Two patterns of progression were included in Spectrum and
were classiﬁed as slow and fast progression. The fast progression
was based on data from a Thai military cohort, which showed
more rapid progression through HIV stages to death (median
progression times are 8.1 years for men and 8.9 years for
women). The fast progression pattern is used by a few countries
in Asia with evidence of similar patterns, whereas the vast
majority of countries use the slow progression pattern. Figure 1
shows the resulting estimates used for Spectrum for the 200 and
350cells/mm
3 CD4 cell threshold values assuming no treatment
for the slow progression pattern. For men the median time from
seroconversion to eligibility was reduced from 8.2 to 5.8 years
Figure 1 HIV progression by CD4 cell
eligibility criterion using the slow
pattern for males and females.
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Supplementwhen switching ART eligibility criteria from 200 cells/mm
3 to
350 cells/mm
3 (the mean progression time is reduced from 9.1 to
6.7 years). For women the median time from seroconversion
to eligibility was reduced from 8.6 to 6.4 years when switching
the eligibility criteria from 200 cells/mm
3 to 350 cells/mm
3 (the
mean progression time is reduced from 9.5 to 7.4 years).
Survival on ART
To derive the parameter of survival on ART two datasets were
reviewed: the ﬁrst included the review of individual data from
a pooled dataset from a collaborative study and the second was
a literature review of published or presented studies.
Pooled data were analysed from the ART-LINC of the Inter-
national epidemiologic Database to Evaluate AIDS (IeDEA)
collaboration. This collaboration (not directly related to eART-
linc described above) was established in 2003 to characterise the
prognosis of HIV-infected patients treated with ART in
resource-limited settings, to compare the experience between
different settings, delivery modes and types of monitoring, and
to compare outcomes with those observed in industrialised
nations. The ART-LINC collaboration was composed of 19
cohort studies and two networks. The data came from the
following countries: Uganda, Rwanda, Burundi, Kenya, Côte
d’Ivoire, Senegal, Nigeria, Morocco, Zimbabwe, Zambia, South
Africa, Botswana, Malawi, Congo, DR Congo, Thailand, India,
Brazil and Argentina. The data submitted from these sites had
similar data formats allowing the calculation of pooled indica-
tors and comparisons between sites.
11 The last data merge for
the ART-LINC collaboration occurred in 2007e8. Among the
patients in this dataset the baseline median CD4 cell count at
the start of ARTwas 113 cells/mm
3 (IQR 47e187), the median
age was 35 years (IQR 30e41), 60% were women and 54% were
either WHO stages 3 or 4.
In addition, a literature review covering the period 2001e6
12
and updated to cover 2007 and 2008 was conducted to estimate
the survival time on ART.
13 The reviewers screened PubMed/
Medline and Scopus for the 2001e6 review and additionally
searched Current Contents Connect and abstracts from the 2008
international conferences for the 2007 and 2008 update. Eligible
reports included original prospective studies in which adults had
started ART in low and middle-income countries, with reports
of deaths or losses to follow-up. A total of 26 studies was used
for the 2001e6 review. An additional 103 articles and 33
abstracts from international conferences were reviewed in the
updated analysis.
The parameter for survival on ARTwas derived primarily from
survival analysis of cohorts or programmes in lower and middle-
income countries primarily using eligibility criteria for starting
ART of WHO stages 3 or 4 or a CD4 cell count less than
200 cells/mm
3. However, evidence suggests that survival will
change as countries adjust the criteria to start patients on
ART earlier,
14 15 as adopted by the WHO at the end of 2009.
16
Ideally, the models would describe survival based on the CD4
cell levels at the start of treatment. At the time the Spectrum
revisions were made there was very little evidence on which to
base an assumption about better survival with an earlier start on
ART. In addition, very few countries currently have national
data to include in a model from which a graduated survival curve
based on starting CD4 cell levels could be calculated.
Analysis of the pooled ART-LINC data from 2008 suggested
that the probability of death at 1 year was estimated to be 0.06
(0.064 in Africa, 0.048 in Asia and 0.026 in South America).
13
Based on the literature review, the cumulative probability of
death by 12 months ranged from 0.03 to 0.29, depending on the
baseline CD4 cell count in the various populations that initiated
ART. The literature review also found that mortality varied
substantially by geographical region and by average starting
CD4 cell level.
13
Survival time in the years following the ﬁrst year on treat-
ment was also calculated. Using data from ART-LINC the
probability of death between month 12 and month 24 was
estimated to be 0.018. It was estimated at 0.013 between month
24 and month 36 and 0.01 between months 36 and 48. However,
the literature review found higher estimates of mortality in the
years after the ﬁrst year on treatment. The estimated probability
of death between month 12 and month 24 was 0.05 based on
nine studies. Due to the small amount of evidence for survival in
the years after 24 months since start on treatment, the same
probability of death, 0.02, was used for all subsequent years.
Loss to follow-up on ART
The literature review of survival on ART also collated data on
loss to follow-up 12 months after ART initiation. Based on
existing studies in the literature review (56 reports with
appropriate data) between 1% and 15% of patients were lost to
follow-up (this excludes one study in which 59% of patients
were lost to follow-up).
13 Calculating the mean from the studies
we estimate that 10.2% of individuals who started ART were
lost to follow-up at 12 months in lower-income countries
(weighted by sample size).
According to the 2008 ART-LINC data 20% of patients who
started ART were lost to follow-up after 12 months.
13 The
probability of loss to follow-up varied by region: 0.201 in Africa,
0.274 in Asia and 0.102 in South America.
Rosen and colleagues
17 conducted a systematic review of
patient retention in ART programmes in sub-Saharan Africa,
which estimated retention rates (including mortality, loss to
follow-up and discontinuing treatment) of 75.1% at 12 months.
The study looked speciﬁcally at non-research programmes. The
authors do not provide estimates of loss to follow-up alone;
however, they do estimate that mortality was on average 4.2%,
making the estimated loss to follow-up rate somewhere just
below 20.7% (assuming that the percentage discontinuing
treatment but remaining in care is very small).
A simple average of the above three statistics provided a value
of 17% patients lost to follow-up at 12 months. This value was
applied as an estimate for loss to follow-up for national ART
programmes in the ﬁrst year of ART treatment.
This rate was similar to retention rates at 12 months reported
through national programmes of 79.5% globally and 75.2% in
sub-Saharan Africa.
18 If mortality on ART is approximately 6%
in the ﬁrst year of life, and loss to follow-up on ART is 17%, this
would suggest an approximate 77% retention rate after
12 months (again, assuming the percentage discontinuing
treatment but remaining in care is small).
The ART-LINC data also provided estimates of loss to follow-
up for up to 4 years after initiation of treatment. Based on the
increasing numbers of individuals lost to follow-up each year in
the eART-linc data, we assumed the attrition rate would remain
constant in subsequent years.
Survival of those lost to follow-up
If those lost to follow-up have higher mortality rates than those
still in the ART programme the models based on right-censored
data would underestimate mortality rates in persons living with
HIV. To estimate mortality among those individuals who have
been lost to follow-up, a review was conducted of available
literature by Brinkhof and colleagues.
19 The authors searched
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Sciences Literature (LILACS), Indian Medlars Centre (IndMed)
and African Index Medicus databases and the abstracts of three
conferences for studies that traced patients lost to follow-up to
ascertain their vital status. Key variables considered in the
analysis included the proportion of patients traced, the propor-
tion found to be alive and the proportion that had died.
Mortality data from several studies were combined using
random-effects meta-analysis. Seventeen studies were eligible.
All were from sub-Saharan Africa, except one study from India.
A total of 6420 patients (range 44e1343 patients) was included.
Patients were traced using telephone calls, home visits and
through social networks. Overall, the vital status of 4021
patients could be ascertained (63%, range across studies
45e86%).
19
Among the 4021 patients lost to follow-up 1602 patients had
died (40%, range 12e87%). The combined mortality estimate
was 40% (95% CI 33% to 48%), with substantial between-study
heterogeneity (p<0.0001). When restricting the analysis to
patients starting ART in public programmes in Africa (12
studies), combined mortality was 47% (95% CI 39% to 54%, p
for heterogeneity <0.0001). The authors of that review
concluded that in ART programmes in resource-limited settings
among those lost to follow-up typically 30e60% had died. The
proportion of patients classiﬁed as lost to follow-up who were in
fact patients who had transferred to continue ART in another
ART site ranged from 12% to 54% in the studies reviewed. The
estimate restricted to the public programmes (47%) was deter-
mined to be the value most appropriate for the national
programmes using Spectrum.
The estimate of 47% mortality can be assumed to be in the
ﬁrst year. The study was not able to provide the mortality levels
over different time periods so the same value was used for
subsequent years.
Based on the above information the parameters described in
table 1 were used in the Spectrum model to describe the survival
of those adults who start ART programmes.
CHILDREN
In July 2008, Unicef, UNAIDS and WHO sponsored a consulta-
tion to review the parameters related to children in Spectrum.
Two studies were commissioned for this consultation to deter-
mine child HIV progression parameters for Spectrum.
20
A description of the derivation of the parameters related to
time from overall seroconversion to death for children is
provided elsewhere.
2 In brief, a recent pooled analysis used
results from eight study sites to create separate survival sched-
ules for children infected perinatally and those infected through
breastfeeding.
21 Progression from HIV seroconversion to death
was revised to follow these schedules in Spectrum.
Seroconversion until need for treatment
In the 2009 version of Spectrum eligibility criteria for children
are now adjustable to match the country’s treatment strategy.
The default settings in Spectrum reﬂect the timing and criteria
of the WHO guidelines as they have been implemented. From
2000 until 2006 eligibility for ARTamong children was based on
a graduated CD4 cell count or percentage depending on age (see
table 2). From 2007 to 2009 the guidelines stated that all children
identiﬁed as HIV positive under 12 months were eligible. In 2010
WHO published revised guidelines recommending that all HIV-
positive children under 24 months be provided with ART and
children aged 24e59 months were eligible for ART if their CD4
cell percentage was less than 25% or CD4 cell count was less
than 750 cells/mm
3.
22
Spectrum estimates the proportion of HIV-infected children
eligible for treatment by using patterns of the distribution of
HIV-infected children by CD4 cell count or CD4 cell percentage.
These patterns were derived from the HIV Paediatric Prognostic
Markers Collaborative Study (HPPMCS), which took place in
western countries before ART was available. This is a unique
dataset because it includes data on CD4 cell percentage and
count in a setting in which no ART is available. Such data are
not available from low and middle-income countries. The study
included a meta-analysis of individual longitudinal data on 3941
HIV-1-infected children enrolled in cohort studies and rando-
mised control trials in the USA and Europe. Care was taken to
avoid using the same children in multiple studies.
23
The distribution of CD4 cell count and percentage CD4 cells
from HPPMCS provide a basis by which to progress children
from birth to the need for treatment in the Spectrum model. All
HIV-infected children less than 1 year old are assigned the CD4
cell distributions from the HPPMCS. The patterns in ﬁgure 2
were used to calculate the proportion of HIV-infected children at
each age and CD4 cell category that remain in the same CD4 cell
category the following year or drop down to a lower CD4 cell
category. Spectrum thus reproduces these patterns in the
absence of ARTand the number of children eligible for ART by
age can be determined based on the country-speciﬁc eligibility
criteria. As ARTcoverage increases children are drawn from the
eligible categories leaving an altered distribution of HIV-infected
children who are not on ART.
Survival on ART
In 2008, Dabis and colleagues conducted a literature review on
child survival on ART in lower-income countries on behalf of
Table 1 Calculation of adult survival parameters used in Spectrum
Survival in ﬁrst year
Mortality rate in ﬁrst year of treatment 0.06
Proportion lost to follow-up 0.17
Mortality rate of those lost to follow-up 0.47
Survival at end of ﬁrst year 1 (0.06+(0.17*0.47))¼0.86
Survival in subsequent years
Mortality rate in subsequent years 0.02
Proportion lost to follow-up 0.17
Mortality rate of those lost to follow-up 0.47
Survival in subsequent years 1 (0.02+(0.17*0.47))¼0.90
Table 2 Default ART eligibility criteria for children in Spectrum
2000e6 2007e9 2010e15
Age below which all HIV-positive children
receive treatment (months)
01 2 2 4
CD4 cell count threshold for eligibility
Age <11 months 1500 1500 750
Age 12e35 months 750 750 750
Age 35e59 months 350 350 750
Age $5 years 200 200 350
CD4 cell percentage threshold for eligibility
Age <11 months 25 25 25
Age 12e35 months 25 25 25
Age 35e59 months 25 25 25
Age $5 years 15 15 15
ART, antiretroviral therapy.
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SupplementUnicef. Articles were selected after screening of PubMed/
Medline and Scopus up to March 2008 and abstracts of 2007e8
international conferences. Observational cohorts, clinical trials
and programme reports were eligible as long as they took place
in lower-income countries and included children on ART or on
ARTand cotrimoxazole. Only studies with death as the outcome
were included in this paediatric ART review update. The
extracted data included patient’s demographic characteristics,
baseline CD4 cell count, survival estimates and factors associ-
ated with mortality of children receiving cotrimoxazole and/or
ART. A total of 14 prospective studies was eligible for the
analysis.
20
The amount of data on the survival of HIV-infected children
on ART in lower and middle income countries more than
doubled since a previous review that covered a period ending in
December 2006.
12 Sample sizes were generally larger, exceeding
400 participants for some of the studies, thereby increasing the
accuracy of the ﬁndings. Some reports allowed for the produc-
tion of survival estimates up to 24 months after ART initiation.
The authors concluded that the probability that infants
survive the ﬁrst year of treatment was estimated to be
0.93e0.95 and survival until 2 years was estimated to be
0.91e0.92. The authors estimated that the provision of co-
trimoxazole along with ART additionally reduced mortality by
approximately 33% in the ﬁrst year, 16% in the second year and
8% in the third year.
20 Spectrum allows the user to specify the
proportion of HIV-exposed children receiving cotrimoxazole and
adjusts mortality accordingly.
Loss to follow-up on ART
The above study also compiled available data on loss to follow-
up among children. Very few data were available at the time of
ﬁnalising the Spectrum model, resulting in the use of expert
opinion to estimate the parameter. The model assumes that an
estimated 10% of children were lost to follow-up and among
those, 50% were expected to have died within 1 year.
Taking into account the additional mortality among those lost
to follow-up, the estimated survival among those children who
started on ART was 0.89 in the ﬁrst year on ART and 0.93 for
subsequent years. To compensate for the increased survival due
to cotrimoxazole, a value of 0.85 was used to describe survival in
the ﬁrst year among children starting ART.
LIMITATIONS
The parameters were derived from the analysis of available
databases and the results published in peer-reviewed scientiﬁc
literature. However, there are a number of limitations due to the
lack of consistency in outcome measures between published
studies and the lack of data available from which to estimate
a robust parameter.
Most of the published articles present survival and retention
for 12 months while only a few studies provide information for
longer durations. Parameters for longer durations will improve
the accuracy of the models.
There could be some overestimation to the loss to follow-up
rates estimated from the ART-LINC of IeDEA data. This data-
base did not systematically record when patients were trans-
ferred to another centre for follow-up. This information may
have been taken into account in some of the other published
studies reducing the comparability of the data. In addition, loss
to follow-up is computed differently depending on the study
site, again reducing the comparability of the data.
The ART-LINC database was composed of 19 cohorts and two
networks and until 2008 constituted the largest available dataset
in lower-income countries. Some data from ART-LINC may
originate from the same clinics as the data used in the individual
cohorts that published articles. It is often difﬁcult to identify
which part of the ART-LINC dataset overlaps with a published
report so all data were used. Also in the systematic review of
published data articles reporting on the same study were
included if the population study was not exactly the same or the
outcomes differed.
The ART-LINC data are very useful for computing such
parameters as they are organised in a single dataset of individual-
level patient data. However, these data do not always reﬂect the
situation at the national level. Many of the sites included in the
ART-LINC data are research or private clinics and are not
representative of the average experience in a public clinic.
In addition the ART-LINC dataset is not large enough to
represent all of the regions where Spectrum is used. Countries in
Europe and Latin America often ﬁnd that the default parameters
in Spectrum do not reﬂect the situation in their countries. In
such cases, countries are encouraged to collect data that might
inform the parameters from their own country. The creation of
regional data centres by the IeDEA initiative of the US National
Institutes of Health in 2007 (http://www.iedea-hiv.org/) will
ultimately lead to regional and possibly country-speciﬁc esti-
mates in the future.
Figure 2 Distribution of CD4 cell count and CD4 cell percentage by
time since seroconversion (year), HIV Paediatric Prognostic Markers
Collaborative Study (HPPMCS).
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parameter varied greatly by average CD4 cell count at the start
of treatment. This was also evident in the ART-LINC estimates
of probability of death. Future versions of Spectrum will incor-
porate an option that allows countries to describe the distribu-
tion of CD4 cell counts at the start of treatment to create a more
accurate estimated duration of survival on ART. In addition, loss
to -follow-up varies by CD4 cell count at the start of treatment
according to the ART-LINC data, again suggesting the need to
create a model that varies the retention on ART parameter
estimate based on average starting CD4 cell values. If countries
are able to populate the models with the distribution of starting
CD4 cell counts the need for region-speciﬁc parameters will be
reduced.
Finally, the data on HIV progression from the HPPMCS study
among children in the USA and western Europe could poten-
tially be different than in low and middle-income country
settings where children have different nutrition levels and
underlying health.
CONCLUSIONS
The UNAIDS HIV estimates published in 2010 are based on
recent evidence. Data describing survival on ART for adults and
children were used to reﬁne the estimate of survival in the ﬁrst
year of ART and the subsequent years for adults and children.
Ideally, countries will use their own country-speciﬁc data on
ARTsurvival, loss to follow-up and survival among those lost to
follow-up in Spectrum to create more accurate estimates of the
impact of HIVon their populations. However, when those data
are not available default parameters are included in the
programme (see table 3).
Since the use of Spectrum by countries to create national
estimates, additional data have become available to inform the
validity of these parameters. More recent studies show that
mortality among adults lost to follow-up actually decreases in
subsequent years.
24e26 In future models the parameters will
indicate lower mortality in patients lost to follow-up after the
ﬁrst year on ART. A recently conducted analysis of loss to
follow-up data of children on ART indicated that the percentage
lost to follow-up at 18 months was 12.3% among 13 611 chil-
dren on ART in the context of the IeDEA initiative. Analysing
these data by region found signiﬁcant variation by region: 4.1%
in Asia; 14.0% in east Africa; 9.0% in southern Africa and 21.8%
in west Africa (p<0.0001).
27
To improve the accuracy of estimates, countries should
compare mortality among those lost to follow-up to death
registries where available. Two recent studies from South Africa
were able to correct mortality estimates and more accurately
estimate programme effectiveness by linking results to vital
registration information.
16 18
Although countries are encouraged to monitor retention rates
in ART programmes routinely,
28 those data can not be used
directly in the Spectrum model at this point. Spectrum requires
information on the survival of those persons in the ART
programme as well as those lost to follow-up in order to progress
each subpopulation accurately.
The default parameters used in Spectrum are calculated for
low and middle-income countries. These parameters might not
be appropriate for models of epidemics in high-income countries.
HIV estimates for high-income countries are currently still
derived using Spectrum due to a lack of alternative models.
The Spectrum parameters and functions related to time from
seroconversion to treatment eligibility and survival on ART have
been regularly updated based on available data and model needs.
The new capability to adjust both child and adult eligibility
criteria will make the model more appropriate for the existing
situations in countries. Additional recent data on survival on
ART for adults and children were incorporated to reﬁne the
estimate of survival in the ﬁrst year of ARTand the subsequent
years for adults and children. The addition of information on
loss to follow-up and survival among those lost to follow-up will
improve the estimates of AIDS-related mortality as well as those
in need of treatment.
Every 2 years the parameters in Spectrum will continue to be
revised as additional data become available. This process has
improved the accuracy and precision of HIV estimates and
projections over the past 10 years.
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Key messages
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